Eton Pharmaceuticals (ETON) earnings history
Most recent quarter
- Fiscal period
- Q2 2026
- Period end
- Jun 30, 2026
- EPS actual
- $0.35
- EPS estimate
- $0.15
- EPS surprise
- +137.45%
- Revenue surprise
- +38.67%
- Revenue
- $37.6M
- Revenue estimate
- $27.1M
- Reported
- Aug 13, 2026
Eton Pharmaceuticals reported Q2 2026 results on August 13, 2026. EPS was $0.35, well above the $0.15 estimate, a 137.45% beat. Revenue reached $37.6 million against a $27.1 million estimate. A year earlier, Q2 2025 was a loss of $0.10 per share on revenue of $18.9 million, so revenue nearly doubled, up 98.9%.
The table shows a company moving from losses to profits. Twelve of the 20 quarters were losses, the latest in Q2 2025. Annual EPS was a loss of $0.35 in 2022, $0.03 in 2023 and $0.15 in 2024, then a small profit of $0.05 in 2025. Revenue rose from $21.3 million in 2022 to $80.0 million in 2025. The last four quarters were all profitable, and Q2 2026 set the highs in the table for both EPS and revenue. Against estimates the record is mixed: 10 beats and 10 misses over the last 20 quarters, with large percentage surprises because many estimates were close to zero.
Eton reported Q3 between November 6 and November 15 in each of the past five years, which points to early or mid-November 2026 for the next report. It will show whether profits hold after four positive quarters in a row.
Earnings history
| Period | Reported | EPS estimate | EPS actual | Surprise | Revenue | Filing |
|---|---|---|---|---|---|---|
| Q2 2026 | Aug 13, 2026 | $0.15 | $0.35 | +137.45% | $37.6M | SEC |
| Q1 2026 | May 14, 2026 | $0.11 | $0.14 | +23.57% | $24.3M | SEC |
| Q4 2025 | Mar 19, 2026 | $0.13 | $0.17 | +27.53% | $21.3M | SEC |
| Q3 2025 | Nov 6, 2025 | $0.09 | $0.04 | −55.56% | $22.5M | SEC |
| Q2 2025 | Aug 7, 2025 | −$0.04 | −$0.10 | −172.48% | $18.9M | SEC |
| Q1 2025 | May 13, 2025 | $0.05 | −$0.06 | −212.57% | $17.3M | SEC |
| Q4 2024 | Mar 18, 2025 | −$0.00 | −$0.02 | −506.06% | $11.6M | SEC |
| Q3 2024 | Nov 12, 2024 | −$0.01 | $0.02 | +300.00% | $10.3M | SEC |
| Q2 2024 | Aug 8, 2024 | −$0.07 | −$0.12 | −71.43% | $9.1M | SEC |
| Q1 2024 | May 9, 2024 | −$0.07 | −$0.03 | +57.14% | $8.0M | SEC |
| Q4 2023 | Mar 14, 2024 | −$0.04 | −$0.09 | −125.00% | $7.3M | SEC |
| Q3 2023 | Nov 9, 2023 | −$0.10 | −$0.02 | +80.00% | $7.0M | SEC |
| Q2 2023 | Aug 10, 2023 | −$0.09 | $0.18 | +300.00% | $12.0M | SEC |
| Q1 2023 | May 11, 2023 | −$0.14 | −$0.10 | +28.57% | $5.3M | SEC |
| Q4 2022 | Mar 16, 2023 | $0.01 | $0.04 | +300.00% | $8.5M | SEC |
| Q3 2022 | Nov 10, 2022 | −$0.15 | −$0.12 | +20.00% | $3.2M | — |
| Q2 2022 | Aug 11, 2022 | $0.03 | −$0.06 | −300.00% | $7.4M | — |
| Q1 2022 | May 12, 2022 | −$0.08 | −$0.21 | −162.50% | $2.2M | — |
| Q4 2021 | Mar 16, 2022 | $0.05 | $0.04 | −20.00% | $6.1M | — |
| Q3 2021 | Nov 15, 2021 | −$0.14 | −$0.24 | −77.78% | $775,000.00 | — |
Quarterly revenue
Frequently asked questions
When did Eton Pharmaceuticals (ETON) last report earnings?
Eton Pharmaceuticals last reported on Aug 13, 2026, covering fiscal Q2 2026.
Did ETON beat earnings estimates?
Yes. Eton Pharmaceuticals reported EPS of $0.35 for Q2 2026 against a $0.15 estimate — a 137.45% beat.
How much revenue did ETON report last quarter?
Eton Pharmaceuticals reported $37.6M in revenue for Q2 2026, against a consensus estimate of $27.1M.
Earnings figures may be restated, revised or corrected by the issuer. Past results do not indicate future performance.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.